Arvinas, Inc.
NASDAQ:ARVN
Overview | Financials
Company Name | Arvinas, Inc. |
Symbol | ARVN |
Currency | USD |
Price | 17.22 |
Market Cap | 1,183,239,582 |
Dividend Yield | 0% |
52-week-range | 17.09 - 53.08 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. John G. Houston Ph.D. |
Website | https://www.arvinas.com |
An error occurred while fetching data.
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD